# India Targeted Liposomes Drug Delivery Market

> India Targeted Liposomes Drug Delivery Market Research Report By Type (Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B, others) and By Application (Fungal Infection Therapy, Cancer Therapy, others) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 7.97%
- **2024:** $ 107.11 Million
- **2025:** $ 115.65 Million
- **2035:** $ 248.97 Million
- **Key Players:** Celsion Corporation (US), AstraZeneca PLC (GB), Johnson & Johnson (US), Pfizer Inc. (US), Novartis AG (CH), Bristol-Myers Squibb Company (US), Gilead Sciences Inc. (US), Roche Holding AG (CH)

**Report ID:** MRFR/Pharma/49797-HCR · **Pages:** 200 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** February 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/india-targeted-liposomes-drug-delivery-market-51555

---

## Market Summary

## **India Targeted Liposomes Drug Delivery Market Overview**

As per MRFR analysis, the India Targeted Liposomes Drug Delivery Market Size was estimated at 124 (USD Million) in 2023. The India Targeted Liposomes Drug Delivery Market Industry is expected to grow from 133.5(USD Million) in 2024 to 620.52 (USD Million) by 2035. The India Targeted Liposomes Drug Delivery Market CAGR (growth rate) is expected to be around 14.99% during the forecast period (2025 - 2035).

**Key India Targeted Liposomes Drug Delivery Market Trends Highlighted**

The India Targeted Liposomes Drug Delivery Market is witnessing significant growth driven by several key market drivers. The increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disorders is prompting the need for innovative drug delivery systems that enhance therapeutic efficacy while minimizing side effects. Moreover, the Indian government is actively supporting research and development in the pharmaceutical sector, leading to advancements in targeted drug delivery technologies. 

This favorable regulatory environment encourages local and international players to invest in India, further expanding the market. Opportunities to be explored include the rising demand for personalized medicine, which aligns well with targeted liposome technologies.The emphasis on localised production of liposomal formulations is anticipated to increase as India continues to improve access to novel therapies and enhance its healthcare infrastructure.

Innovation in targeted drug delivery is anticipated to be stimulated by partnerships between academic institutions and industry actors, thereby establishing new opportunities for market expansion. In recent years, there has been a discernible trend towards the development of smart liposomes that are capable of responding to specific biological stimuli. Researchers are striving to develop more efficient and effective delivery mechanisms that can enhance patient outcomes, which is consistent with the rise in R&D activities in India.

Furthermore, the distribution channels in the targeted liposomes market are being impacted by the expansion of e-commerce platforms and online pharmacies, which is altering the way pharmaceutical products are delivered to consumers. India is a rapidly expanding market for targeted liposome drug delivery solutions due to the convergence of advancing health challenges, supportive government policies, and technological advancements.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**India Targeted Liposomes Drug Delivery Market Drivers**

**Rising Incidence of Cancer Diseases in India**

The incidence of cancer in India has seen a significant rise over the years, with recent estimates from the National Cancer Registry Program indicating an approximate 23.7 lakh new cancer cases expected annually by 2025. This alarming rate positions cancer as a critical public health challenge, necessitating advanced treatment modalities. The India Targeted Liposomes Drug Delivery Market Industry stands to benefit from this trend, as targeted therapies using liposomes can deliver drugs more efficiently and with reduced side effects.

Companies like Reliance Life Sciences are investing in innovative targeted drug delivery systems which reflect the necessity for targeted treatments in the Indian healthcare landscape, accordingly pushing the market in the direction of more advanced, effective delivery methods.

**Advancements in Nanotechnology**

Nanotechnology is increasingly being recognized for its revolutionary potential in drug delivery systems, including liposomal formulations. The Indian Government has initiated programs to promote Research and Development in nanotechnology as part of its National Policy on Nano Science and Technology. 

This has led to increased investment in the sector, with reports showing that the Indian nanotechnology market is expected to reach USD 2.3 billion by 2026, growing at a CAGR of 30%.As key players like Cadila Healthcare are incorporating nanotechnology in their drug delivery systems, the advancements are expected to significantly boost the India Targeted Liposomes Drug Delivery Market Industry.

**Growing Geriatric Population**

India's geriatric population is projected to rise dramatically, with an increase from 7.7% in 2021 to 19% by 2050 according to the United Nations. The elderly often have multiple comorbidities, which often necessitate more specialized and effective treatment protocols, including targeted therapies. 

The India Targeted Liposomes Drug Delivery Market Industry is likely to see growth as healthcare providers adopt more effective solutions for elder patient care.Established organizations like the All India Institute of Medical Sciences have restructured their facilities to cater to this demographic, thus promoting the need for advanced drug delivery technologies.

**India Targeted Liposomes Drug Delivery Market Segment Insights**

**Targeted Liposomes Drug Delivery Market Type Insights**

The India Targeted Liposomes Drug Delivery Market has gained significant traction as technological advancements in drug delivery systems have progressed. Among the various types of liposome products, Liposomal Doxorubicin stands out for its effectiveness in treating multiple cancers, thus addressing a critical public health issue in India, where cancer rates are on the rise. The advantages inherent in this formulation, such as improved bioavailability and reduced systemic toxicity, amplify its importance. 

Moreover, Liposomal Paclitaxel serves as another vital component in this market, particularly for its role in enhancing the efficacy of chemotherapy while minimizing adverse effects, making it a preferred choice for oncologists and patients alike.This aligns with the growing need for targeted therapies in India's healthcare landscape, where the emphasis is shifting towards personalized medicine. Liposomal Amphotericin B is significant as it addresses severe fungal infections, which are increasingly common, especially in immunocompromised patients. 

In India, where healthcare resources can be limited, the effectiveness of these targeted therapies in achieving better patient outcomes makes them exceedingly valuable. Furthermore, the 'others' category encapsulates a range of emerging formulations that continue to drive innovation within the market, reflecting an ongoing commitment to research and development initiatives aimed at enhancing drug efficacy and safety profiles.Collectively, these types illustrate a comprehensive approach to managing complex diseases, aligning with broader health initiatives in India aimed at improving treatment strategies and access to advanced therapies. 

The segmentation within the India Targeted Liposomes Drug Delivery Market underscores a crucial framework for understanding the diverse needs and opportunities that exist within the evolving pharmaceutical landscape.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Targeted Liposomes Drug Delivery Market Application Insights**

The Application segment of the India Targeted Liposomes Drug Delivery Market encompasses various therapeutic areas, including Fungal Infection Therapy, Cancer Therapy, and others, which play crucial roles in addressing significant health concerns within the region. With India experiencing high incidences of fungal infections and various cancer types, the importance of targeted liposomal delivery systems becomes clear, as they enhance the therapeutic efficacy while minimizing side effects. Fungal Infection Therapy utilizes liposomes for innovative antifungal drug delivery, resulting in improved patient compliance and treatment outcomes.

Meanwhile, Cancer Therapy is gaining traction, where targeted liposomes can enhance drug delivery to specific tumor sites, improving the effectiveness of chemotherapy agents. As the healthcare landscape in India evolves, other applications emerge, revealing opportunities for development in drug delivery systems, thus driving advancements in Research and Development and addressing unmet medical needs. The diverse applications within this segment reflect broad potential within the India Targeted Liposomes Drug Delivery Market, underscoring the necessity for ongoing innovations and research to meet the growing demands of the healthcare system in the country..

**India Targeted Liposomes Drug Delivery Market Key Players and Competitive Insights**

The India Targeted Liposomes Drug Delivery Market has been evolving rapidly, driven by advancements in nanomedicine, biotechnology, and a growing demand for effective therapeutic options. Targeted liposomes serve as a promising drug delivery system, offering enhanced therapeutic efficacy while minimizing side effects. The competitive landscape of this market is characterized by a blend of established companies and innovative startups focusing on unique formulations and strategic collaborations. 

Companies are increasingly investing in research and development activities to enhance their product offerings and maintain a competitive edge. Factor such as rising healthcare awareness, increasing prevalence of chronic diseases, and an emphasis on personalized medicine are propelling the growth of this market, creating a dynamic environment where innovations define competitive positioning.

Zydus Cadila stands out in the India Targeted Liposomes Drug Delivery Market with its strong commitment to research and development, allowing it to carve a niche in advanced drug delivery systems. The company has developed targeted formulations that address specific disease conditions, enhancing drug absorption and efficacy. Its robust pipeline of products includes several liposomal formulations that cater to high-demand therapeutic areas, making Zydus Cadila a key player in this segment. The extensive presence of Zydus in India, combined with a solid distribution network, has enabled the company to establish significant market penetration. 

Zydus Cadila's strength lies in its unwavering focus on innovation, compliance with regulatory standards, and collaborations with academic and research institutions, enhancing its capacity for impactful developments in targeted drug delivery technologies.Torrent Pharmaceuticals also plays a critical role in the India Targeted Liposomes Drug Delivery Market, focusing on the development of innovative therapies and specialized formulations. The company has been active in creating strategic partnerships and collaborations to expand its footprint in this domain, which has helped it to diversify its product portfolio.

Its strengths lie in a strong manufacturing base and a comprehensive understanding of the pharmaceutical landscape in India. 

Torrent Pharmaceuticals has successfully launched several key products that utilize liposomal technology, promoting better therapeutic outcomes in various disease states. Furthermore, the expansion strategy includes potential mergers and acquisitions that aim to bolster its research capabilities and broaden its market share in the targeted liposomes segment. This proactive approach in aligning with technological advancements and market needs highlights Torrent's significant presence and contribution to the evolving landscape of targeted drug delivery systems in India.

**Key Companies in the India Targeted Liposomes Drug Delivery Market Include:**

**India Targeted Liposomes Drug Delivery Market Industry Developments**

In recent months, the India Targeted Liposomes Drug Delivery Market has witnessed a series of significant developments. Notably, Zydus Cadila received approvals for new liposome-based formulations aimed at improving drug efficacy and minimizing side effects, reflecting a focused effort on Research and Development. Torrent Pharmaceuticals has also been innovating in this domain, announcing advancements in liposome technologies to enhance the therapeutic delivery of oncology drugs. 

In terms of mergers and acquisitions, Glenmark Pharmaceuticals announced in July 2023 its acquisition of Aurigene Pharmaceutical Services to bolster its pipeline in the liposomal delivery space. Meanwhile, Sun Pharmaceutical Industries has expanded its market presence by launching new targeted liposomal formulations for chronic diseases. The overall valuation of the Indian market has been positively impacted, with Intas Pharmaceuticals reporting a significant increase in market share due to strategic partnerships in the region. 

Over the last two years, companies like Cipla and Shilpa Medicare have accelerated their liposome research efforts, aligning with the Indian government's push to promote indigenous drug manufacturing and innovative drug delivery systems, fostering a vibrant landscape for growth in targeted drug delivery solutions.

**India Targeted Liposomes Drug Delivery Market Segmentation Insights**

**Targeted Liposomes Drug Delivery Market Type Outlook**

**Targeted Liposomes Drug Delivery Market Application Outlook**

- Fungal Infection Therapy
- Cancer Therapy

## Market Drivers

### Growing Demand for Biologics

The increasing demand for biologics in India is significantly impacting the targeted liposomes-drug-delivery market. Biologics, which include monoclonal antibodies and vaccines, require sophisticated delivery systems to enhance their therapeutic efficacy. Targeted liposomes can encapsulate these biologics, ensuring they reach their intended site of action while minimizing systemic exposure. The Indian biologics market is projected to grow at a CAGR of over 20% in the coming years, indicating a robust demand for advanced drug delivery systems. This trend suggests that the targeted liposomes-drug-delivery market will likely see increased investment and innovation as pharmaceutical companies strive to meet the needs of patients requiring biologic therapies.

### Rising Healthcare Expenditure

India's increasing healthcare expenditure is a significant driver for the targeted liposomes-drug-delivery market. As the government and private sectors invest more in healthcare infrastructure and services, there is a growing focus on advanced treatment options. The healthcare expenditure in India is expected to reach approximately $370 billion by 2025, reflecting a shift towards more sophisticated medical technologies. This trend indicates that healthcare providers are likely to adopt targeted liposomes as part of their treatment protocols, enhancing patient outcomes and optimizing resource utilization. Consequently, the targeted liposomes-drug-delivery market is poised for growth as healthcare systems evolve to incorporate these innovative solutions.

### Advancements in Nanotechnology

Technological advancements in nanotechnology are playing a crucial role in the evolution of the targeted liposomes-drug-delivery market. Innovations in liposome formulation and production techniques are enhancing the stability, bioavailability, and targeting capabilities of liposomal drugs. For instance, the development of stimuli-responsive liposomes that release drugs in response to specific biological triggers is gaining traction. This could lead to more effective treatments with fewer side effects. The Indian government has recognized the potential of nanotechnology in healthcare, allocating substantial funding for research and development. As a result, the targeted liposomes-drug-delivery market is expected to expand, driven by these technological breakthroughs that improve therapeutic outcomes.

### Increasing Prevalence of Chronic Diseases

The rising incidence of chronic diseases in India, such as cancer, diabetes, and cardiovascular disorders, is driving the targeted liposomes-drug-delivery market. As healthcare providers seek more effective treatment modalities, targeted liposomes offer a promising solution by enhancing drug efficacy and minimizing side effects. Reports indicate that cancer cases in India are projected to reach 1.5 million by 2025, necessitating innovative drug delivery systems. This trend suggests a growing demand for targeted therapies, which could potentially increase the market size significantly. The targeted liposomes-drug-delivery market is likely to benefit from this shift towards more precise and effective treatment options, as healthcare systems adapt to the needs of an aging population and the burden of chronic illnesses.

### Regulatory Support for Advanced Therapies

Regulatory bodies in India are increasingly supportive of advanced therapeutic modalities, which is beneficial for the targeted liposomes-drug-delivery market. The Central Drugs Standard Control Organization (CDSCO) has streamlined approval processes for novel drug delivery systems, encouraging innovation and investment in this sector. This regulatory environment fosters the development of new liposomal formulations that can address unmet medical needs. As a result, pharmaceutical companies are more likely to invest in research and development of targeted liposomes, anticipating a favorable regulatory landscape. This support could potentially accelerate the introduction of new therapies into the market, thereby enhancing the overall growth of the targeted liposomes-drug-delivery market.

## Future Outlook

The [Targeted Liposomes Drug Delivery Market](https://www.marketresearchfuture.com/reports/targeted-liposomes-drug-delivery-market-8756) in India is projected to grow at a 7.97% CAGR from 2025 to 2035, driven by advancements in nanotechnology and increasing demand for targeted therapies.

**New opportunities:**

- Development of personalized liposomal formulations for oncology treatments.
- Expansion of partnerships with biotech firms for innovative drug delivery solutions.
- Investment in R&D for novel liposome manufacturing techniques to enhance efficiency.

By 2035, the market is expected to achieve substantial growth, positioning itself as a leader in drug delivery solutions.

## Segment Insights

### By Type: Liposomal Doxorubicin (Largest) vs. Liposomal Paclitaxel (Fastest-Growing)

In the India targeted liposomes-drug-delivery market, Liposomal Doxorubicin holds the largest market share, benefiting from its established efficacy and widespread use in treating various cancer types. In contrast, Liposomal Paclitaxel is gaining traction as it addresses specific needs for targeted therapy, increasingly being adopted in clinical settings. The segment distribution reflects a competitive landscape with shifting dynamics as healthcare providers seek effective solutions.

Growth trends indicate a positive trajectory, particularly for Liposomal Paclitaxel, which is experiencing rapid adoption due to its improved therapeutic benefits and lower side effects compared to traditional options. Factors such as technological advancements in liposome formulation and increasing investment in cancer treatments are driving market growth. The focus on personalized medicine and targeted drug delivery continues to enhance the appeal of these liposomal formulations.

Liposomal Doxorubicin (Dominant) vs. Liposomal Paclitaxel (Emerging)

Liposomal Doxorubicin remains the dominant force in the market, favored for its proven effectiveness in oncology, particularly for breast cancer and other solid tumors. Its long-standing presence has led to a robust manufacturing and distribution network, ensuring availability across healthcare facilities. In contrast, Liposomal Paclitaxel is emerging as a promising alternative, leveraging advancements in biopharmaceutical technology to enhance efficacy and reduce toxicity. This segment attracts interest due to its targeted delivery system that minimizes adverse effects while maximizing therapeutic impact. Together, these segment values illustrate a landscape marked by both stability and innovation, catering to the evolving needs of patients and healthcare professionals alike.

### By Application: Cancer Therapy (Largest) vs. Fungal Infection Therapy (Fastest-Growing)

In the India targeted liposomes-drug-delivery market, Cancer Therapy holds the largest share, significantly driven by the increasing incidence of cancer cases and the corresponding demand for advanced treatment options. Fungal Infection Therapy remains crucial as well, steadily capturing market presence due to its importance in treating persistent infections, alongside other applications that contribute to the diversified landscape of this market.

The growth trends in this segment are particularly influenced by technological advancements in liposome formulations, enhancing drug delivery efficacy for both cancer and fungal therapies. Furthermore, rising healthcare expenditure and an increasing awareness of targeted therapeutics are propelling these segments forward. Innovation in drug delivery mechanisms is anticipated to drive competition and stimulate market growth over the upcoming years.

Cancer Therapy (Dominant) vs. Fungal Infection Therapy (Emerging)

Cancer Therapy, characterized by its extensive research investments and advanced formulation technologies, dominates the India targeted liposomes-drug-delivery market due to the alarming rise in cancer incidences. The market is witnessing a surge in innovative therapies, with liposomes providing targeted and controlled drug delivery, leading to better patient outcomes. On the contrary, Fungal Infection Therapy, while emerging, is gaining traction as healthcare systems focus on combating increasing fungal infections resulting from rising immunocompromised populations. Both segments demonstrate unique characteristics: Cancer Therapy emphasizes advanced treatments, while Fungal Infection Therapy highlights the necessity for effective management of fungal diseases, thus playing a pivotal role in the market's evolution.

## Competitive Benchmarking

The targeted liposomes-drug-delivery market in India is characterized by a dynamic competitive landscape, driven by increasing demand for advanced therapeutic solutions and a growing focus on precision medicine. Key players such as Celsion Corporation (US), AstraZeneca PLC (GB), and Johnson & Johnson (US) are actively shaping the market through strategic initiatives. Celsion Corporation (US) appears to be concentrating on innovation, particularly in the development of its proprietary ThermoDox® technology, which utilizes liposomal drug delivery for enhanced cancer treatment efficacy. Meanwhile, AstraZeneca PLC (GB) is focusing on regional expansion, having recently established a new research facility in India aimed at accelerating drug development processes tailored to local needs. Johnson & Johnson (US) is also investing in partnerships with local biotech firms to enhance its product pipeline, indicating a collaborative approach to market penetration.The business tactics employed by these companies reflect a trend towards localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market structure is moderately fragmented, with several players vying for market share, yet the collective influence of major companies is significant. This competitive environment fosters innovation and drives advancements in liposomal formulations, which are crucial for improving drug delivery systems.

In October  Celsion Corporation (US) announced a strategic partnership with a leading Indian pharmaceutical company to co-develop a new liposomal formulation aimed at treating breast cancer. This collaboration is expected to leverage local expertise and resources, potentially accelerating the development timeline and enhancing market access. The strategic importance of this partnership lies in its ability to combine Celsion's innovative technology with the local partner's distribution network, thereby increasing the reach of their product offerings.

In September  AstraZeneca PLC (GB) launched a new liposomal drug delivery system specifically designed for targeted cancer therapies in India. This launch is indicative of the company's commitment to addressing unmet medical needs in the region. By introducing this advanced delivery system, AstraZeneca aims to improve therapeutic outcomes and solidify its position as a leader in oncology solutions. The strategic importance of this initiative is underscored by the growing prevalence of cancer in India, which necessitates innovative treatment options.

In August  Johnson & Johnson (US) expanded its liposomal drug delivery portfolio by acquiring a small biotech firm specializing in nanotechnology. This acquisition is likely to enhance Johnson & Johnson's capabilities in developing next-generation liposomal formulations. The strategic significance of this move lies in the potential for integrating cutting-edge nanotechnology into their existing product lines, thereby improving drug efficacy and patient outcomes.

As of November  current competitive trends in the targeted liposomes-drug-delivery market include a pronounced emphasis on digitalization, sustainability, and the integration of artificial intelligence (AI) in drug development processes. Strategic alliances are increasingly shaping the landscape, as companies recognize the value of collaboration in driving innovation. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition towards a focus on technological advancements, innovative solutions, and reliable supply chains. This transition may redefine market dynamics, positioning companies that prioritize R&D and strategic partnerships at the forefront of the industry.

## Recent News & Developments

In recent months, the India Targeted Liposomes Drug Delivery Market has witnessed a series of significant developments. Notably, Zydus Cadila received approvals for new liposome-based formulations aimed at improving drug efficacy and minimizing side effects, reflecting a focused effort on Research and Development. Torrent Pharmaceuticals has also been innovating in this domain, announcing advancements in liposome technologies to enhance the therapeutic delivery of oncology drugs. 

In terms of mergers and acquisitions, Glenmark Pharmaceuticals announced in July 2023 its acquisition of Aurigene Pharmaceutical Services to bolster its pipeline in the liposomal delivery space. Meanwhile, Sun Pharmaceutical Industries has expanded its market presence by launching new targeted liposomal formulations for chronic diseases. The overall valuation of the Indian market has been positively impacted, with Intas Pharmaceuticals reporting a significant increase in market share due to strategic partnerships in the region. 

Over the last two years, companies like Cipla and Shilpa Medicare have accelerated their liposome research efforts, aligning with the Indian government's push to promote indigenous drug manufacturing and innovative drug delivery systems, fostering a vibrant landscape for growth in targeted drug delivery solutions.

## Report Scope

| MARKET SIZE 2024 | 107.11(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 115.65(USD Million) |
| MARKET SIZE 2035 | 248.97(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.97% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Celsion Corporation (US), AstraZeneca PLC (GB), Johnson & Johnson (US), Pfizer Inc. (US), Novartis AG (CH), Bristol-Myers Squibb Company (US), Gilead Sciences Inc. (US), Roche Holding AG (CH) |
| Segments Covered | Type, Application |
| Key Market Opportunities | Advancements in targeted liposomes-drug-delivery technologies enhance precision medicine and therapeutic efficacy. |
| Key Market Dynamics | Rising demand for targeted therapies drives innovation in liposome-based drug delivery systems within the Indian market. |
| Countries Covered | India |

## Frequently Asked Questions

**Q: What was the market valuation of the targeted liposomes-drug-delivery market in 2024?**
A: The market valuation was $107.11 Million in 2024.

**Q: What is the projected market valuation for the targeted liposomes-drug-delivery market by 2035?**
A: The projected valuation for 2035 is $248.97 Million.

**Q: What is the expected CAGR for the targeted liposomes-drug-delivery market during the forecast period 2025 - 2035?**
A: The expected CAGR is 7.97% during the forecast period 2025 - 2035.

**Q: Which companies are considered key players in the targeted liposomes-drug-delivery market?**
A: Key players include Celsion Corporation, AstraZeneca PLC, Johnson & Johnson, Pfizer Inc., Novartis AG, Bristol-Myers Squibb Company, Gilead Sciences Inc., and Roche Holding AG.

**Q: What are the main types of liposomes used in drug delivery, and what were their valuations in 2024?**
A: In 2024, Liposomal Doxorubicin was valued at $30.0 Million, Liposomal Paclitaxel at $25.0 Million, Liposomal Amphotericin B at $20.0 Million, and Others at $32.11 Million.

**Q: What applications dominate the targeted liposomes-drug-delivery market?**
A: Cancer Therapy (Tumor Therapy) dominated with a valuation of $70.0 Million in 2024, followed by Fungal Infection Therapy at $10.71 Million.

**Q: How does the valuation of Cancer Therapy compare to other applications in 2024?**
A: In 2024, Cancer Therapy was valued at $70.0 Million, significantly higher than Fungal Infection Therapy, which was valued at $10.71 Million.

**Q: What is the potential growth outlook for the targeted liposomes-drug-delivery market?**
A: The market appears poised for growth, with a projected valuation increase to $248.97 Million by 2035.

**Q: What were the valuations for the 'Others' segment in both types and applications in 2024?**
A: In 2024, the 'Others' segment for types was valued at $32.11 Million, while for applications, it was valued at $26.4 Million.

**Q: How do the valuations of Liposomal Paclitaxel and Liposomal Amphotericin B compare in 2024?**
A: In 2024, Liposomal Paclitaxel was valued at $25.0 Million, while Liposomal Amphotericin B was valued at $20.0 Million, indicating a higher valuation for Paclitaxel.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/india-targeted-liposomes-drug-delivery-market-51555*